Apixaban is indicated for:
Population group: both men and women, only adults (18 years old or older)
Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Apixaban is contraindicated in the following cases: